ONL Therapeutics
PrivateLast Round
Series D
Sep 13, 2024
Total Funding Raised
$150.35M
Company Overview
ONL Therapeutics is a biopharmaceutical company that develops first-in-class therapeutics to protect and improve the vision of patients with retinal diseases and conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ONL Therapeutics Comparables
Compare ONL Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astellas Pharma Inc. | 80% | |
| Aviceda Therapeutics | 80% | |
| Kyoto Drug Discovery & Development Co., Ltd. | 78% |
ONL Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 13, 2024 | ||||
| VC Round | Mar 12, 2024 | ||||
| Series C | Aug 1, 2023 | ||||
| Series C | Mar 8, 2023 | ||||
| Series B | Dec 22, 2020 | ||||
Convertible Debt | Aug 15, 2019 |
Key People
Founding team and executive leadership
ONL Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kaitai Capital | Series C, Series B |
| Hestia Investments | Series A |
| Biosciences Research & Commercialization Center | Convertible Debt, Series C, Series B, Series A |
| Michigan Investment in New Technology Startups | Convertible Debt, Series B, Series C, Series A |
| Mayewell Capital | Series C |
| Michigan Capital Network | Convertible Debt, Series B, Series C |
| Michigan Strategic Fund | Debt, VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2025
Presented at the FLORetina-ICOOR Congress 2025.
- Nov 10, 2025
Will present at the EYENOVATE conference.
Recent news
Latest coverage and updates
- attends_eventAug 10, 2026
ONL Therapeutics, Inc. will attend event The Business of Life Sciences on Sep 29th '26.
ONL Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ONL Therapeutics's valuation, stock price, and market status.
Is ONL Therapeutics a public or private company?
ONL Therapeutics is a private company.
What is the current stock price of ONL Therapeutics?
ONL Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is ONL Therapeutics worth (valuation)?
Valuation information for ONL Therapeutics is not publicly available.
Can I buy ONL Therapeutics stock?
ONL Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ONL Therapeutics's last funding round?
ONL Therapeutics's most recent funding round was Series D on September 13, 2024.
Who are the main investors in ONL Therapeutics?
Key investors in ONL Therapeutics include InFocus Capital Partners, Johnson & Johnson Innovation - JJDC, Inc., Bios Partners.
Will ONL Therapeutics IPO soon?
No public IPO plans have been announced for ONL Therapeutics.
How can I track ONL Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ONL Therapeutics's secondary market activity and sign up for updates.